Role of alcohol in nonalcoholic steatohepatitis: Rush university (Con) patients with nonalcoholic steatohepatitis should be abstinent from alcohol use
Maham Lodhi, Jaimin Amin, Sheila Eswaran – 28 February 2018
Pure Laparoscopic Living Donor Left Lateral Sectionectomy in Pediatric Transplantation: A Propensity Score Analysis on 220 Consecutive Patients
Dieter C. Broering, Yasser Elsheikh, Mohammed Shagrani, Faisal Abaalkhail, Roberto I. Troisi – 28 February 2018 – Left lateral sectionectomy for donor hepatectomy is a well‐established alternative to deceased donor pediatric liver transplantation. However, very little is available on the laparoscopic approach (laparoscopic left lateral sectionectomy [L‐LLS]).
Hilar cholangiocarcinoma associated with immunoglobulin G4‐positive plasma cells and elevated serum immunoglobulin G4 levels
Nabeel Azeem, Veeral Ajmera, Bilal Hameed, Neil Mehta – 28 February 2018 – Immunoglobulin G4 (IgG4)‐related disease is a fibroinflammatory systemic disorder with multiorgan involvement. Proximal bile duct involvement results in IgG4‐related sclerosing cholangitis, which is characterized by a lymphoplasmacytic infiltrate with abundant IgG4‐positive plasma cells and fibrosis. Differentiating between cholangiocarcinoma and IgG4‐sclerosing cholangitis can present a diagnostic dilemma.
Arresting frailty and sarcopenia in cirrhosis: Future prospects
Hui‐Wei Chen, Michael A. Dunn – 28 February 2018
The Role of Intestinal C‐type Regenerating Islet Derived‐3 Lectins for Nonalcoholic Steatohepatitis
Sena Bluemel, Lirui Wang, Cameron Martino, Suhan Lee, Yanhan Wang, Brandon Williams, Angela Horvath, Vanessa Stadlbauer, Karsten Zengler, Bernd Schnabl – 28 February 2018 – C‐type regenerating islet derived‐3 (Reg3) lectins defend against pathogens and keep commensal bacteria at a distance. Deficiency of Reg3g and Reg3b facilitates alcohol‐induced bacterial translocation and alcoholic liver disease. Intestinal Reg3g is down‐regulated in animal models of diet‐induced obesity, but the functional consequences for nonalcoholic steatohepatitis (NASH) are unknown.
Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas
Wouter Moest, Wendy van der Deure, Ted Koster, Marcela Spee‐Dropková, Linda Swart‐Busscher, Robbert J. de Haas, Terry G.J. Derks – 27 February 2018
Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy
Jia‐Feng Wu, Chee‐Seng Lee, Wen‐Hsi Lin, Yung‐Ming Jeng, Huey‐Ling Chen, Yen‐Hsuan Ni, Hong‐Yuan Hsu, Mei‐Hwei Chang – 27 February 2018 – We investigated the utility of transient elastography (TE) for diagnosing biliary atresia (BA) in cholestatic infants and predicting the outcome of BA. Forty‐eight cholestatic infants (9‐87 days of age) with direct bilirubin level >1 mg/dL were enrolled. Liver stiffness measurement (LSM) by TE was performed during the cholestasis workup, and 15 subjects were diagnosed as BA.
Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolism
Preeti Pathak, Cen Xie, Robert G. Nichols, Jessica M. Ferrell, Shannon Boehme, Kristopher W. Krausz, Andrew D. Patterson, Frank J. Gonzalez, John Y.L. Chiang – 27 February 2018 – Bile acids activate farnesoid X receptor (FXR) and G protein–coupled bile acid receptor‐1 (aka Takeda G protein–coupled receptor‐5 [TGR5]) to regulate bile acid metabolism and glucose and insulin sensitivity. FXR and TGR5 are coexpressed in the enteroendocrine L cells, but their roles in integrated regulation of metabolism are not completely understood.
Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas
Wouter Moest, Wendy van der Deure, Ted Koster, Marcela Spee‐Dropková, Linda Swart‐Busscher, Robbert J. de Haas, Terry G.J. Derks – 27 February 2018
Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort
Paul Kwo, Michael W. Fried, K. Rajender Reddy, Consuelo Soldevila‐Pico, Saro Khemichian, Jama Darling, Phillippe J. Zamor, Andrew A. Napoli, Beatrice Anduze‐Faris, Robert S. Brown – 27 February 2018 – We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child‐Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus infection and advanced fibrosis/cirrhosis.